Charles River Updates 2017 Guidance

Third-quarter earnings per share on a non-GAAP basis were $1.30, an increase of 10.2% from $1.18 per share for the third quarter of 2016.

Institutional investors now hold around $5.53 billion or 0% in CRL stock. First Quadrant L P CA's holdings in Charles River Laboratories International were worth $15,680,000 at the end of the most recent reporting period.

Investors have the ability to use technical indicators when completing stock research. Charles River Laboratories now has $4.88 billion valuation. William Blair analyst J. Kreger anticipates that the medical research company will post earnings per share of $1.34 for the quarter. OppenheimerFunds Inc. grew its stake in shares of Charles River Laboratories International by 9.1% during the 1st quarter. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The last close places the company's stock about $6.27 off its 52 week high of $116.4 and $18.04 above the 52 week low of $92.09. LaSalle Street Capital Management LLC bought a new stake in Charles River Laboratories International during the second quarter valued at $215,000. The Volatility 3m of Charles River Laboratories International, Inc. Charles River Laboratories International now has a consensus rating of "Buy" and a consensus target price of $103.77. If Charles River Laboratories International, Inc. (NYSE:CRL) recovered 47.96% of its value since hitting low of $69.51.

FY2017 EPS Estimates for Bank of Nova Scotia (The) Decreased by Desjardins (BNS)
The company has a market cap of $78,518.63, a PE ratio of 13.37, a price-to-earnings-growth ratio of 1.52 and a beta of 1.28. Piermont Cap has invested 0.22% in Silgan Holdings Inc. 23,490 were reported by New Mexico Educational Retirement Board.

About 1.66M shares traded. It has been assigned a low target price of $75 and a high target price of $135. Values of %D line that are above 80 indicate that the security is overbought; prices could well fall in the near future. The company has a 50-day moving average price of $73.95 and a 200-day moving average price of $81.20. At the time of writing, the 14-day ADX for Charles River Laboratories Intl (CRL) is standing at 52.45. The firm had revenue of $425.70 million for the quarter, compared to the consensus estimate of $291.20 million. Over the past month the firm's stock is 5.37%, 21.79% for the last quarter, 33.51% for the past six-months and 63.38% for the a year ago. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years.

A number of analysts offered their Estimated Earnings analysis for Charles River Laboratories International, Inc. "(CRL)" was reported by Us and is the propert of of Us. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and global trademark & copyright laws. Moreover, Leavell Mngmt Incorporated has 0.06% invested in Charles River Laboratories Intl. (NYSE:CRL), with 9 analysts believing it is a strong buy. Zacks Investment Research upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $93.00 price objective for the company in a research note on Wednesday, October 5th. Jefferies Group LLC boosted their price target on Charles River Laboratories International from $120.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, October 9th. Finally, Credit Suisse Group AG reiterated a "neutral" rating on shares of Charles River Laboratories International in a research note on Friday, September 30th. The third largest holder is Fmr Llc, which now holds $362.73 million worth of this stock and that ownership represents almost 7.45% of its market capitalization. The count of Hold ratings in that period was 7. On the other side of RSI values, an RSI reading of 30 or below is commonly interpreted as indicating an oversold or undervalued condition that may signal a trend change or corrective price reversal to the upside. Following the completion of the transaction, the insider now owns 20,424 shares in the company, valued at approximately $2,040,561.84. 05, 2017, the shares were put up for sale at an average price of $107.55, raking in a sum of $643,364. The company had a trading volume of 150,201 shares, compared to its average volume of 375,540. The disclosure for this sale can be found here. Partners Ltd Limited Liability Company stated it has 0.52% in Charles River Laboratories Intl. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Latest News